Björn Larsson has solid experience from the global medical device and pharmaceutical industry where he has held various positions in companies such as ABIGO Medical AB and AstraZeneca.
"I look forward to leading the company into the next phase and, together with the board and the team, realizing the potential of RLS' unique, patented hypochlorite platform, ChloraSolv. With my experience in the field of wound care, I am convinced that RLS' technology and product portfolio can add significant clinical value and contribute to improved and more efficient care and increased quality of life for the patient", says Larsson.
In recent years, RLS Global has evolved into a commercial wound care company. The company's strategic focus is to develop ChloraSolv to include new indications and therapeutic areas such as burns, pressure ulcers and animal care, through clinical studies that generate further clinical evidence. In addition, RLS Global focuses on geographic expansion in partnership with ConvaTec and other leading partners.
"It is with pleasure that I welcome Björn Larsson to lead RLS Global into the future. I am convinced that Björn, with his solid experience in medical device, pharmaceuticals and wound care, will lead the commercialization and further development of ChloraSolv in a successful way.
I also want to thank Karin Fischer for her contribution as CEO of RLS Global and wish her the best of luck in her new challenge", says Steve Krognes, Chairman of the Board.

RLS Global (publ) is obliged to make the information contained herein public pursuant to the EU market abuse regulation (MAR). The information was submitted for publication through the agency of the above contact person, 23-08-2022 09:00 CET.